Skip to main content

Discovering novel antibodies derived from the human body itself to treat neurodegenerative diseases

Project description

An eagle's eye for antibodies associated with rare diseases may revolutionise therapy

Neurodegenerative diseases are a large family of disorders characterised by progressive degeneration of the structure and function of the nervous system. While great strides have been made in understanding the causes and progression of many of these diseases, treatment and ultimately prevention is still quite challenging. Human-derived antibodies that can recognise threats with high specificity and mount a defence with minimal side effects hold great but largely unreleased potential to combat neurodegenerative disease processes. The Swiss biotech company Mabylon has developed powerful technologies to screen for some of the rarest antibodies. With the EU-funded HominAb project, scientists are laying the groundwork for commercialisation of their screening platform to target diseases including amyotrophic lateral sclerosis and frontotemporal dementia.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

MABYLON AG
Net EU contribution
€ 50 000,00
Address
Wagistrasse 14
8952 Schlieren
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00